A Phase 3 Trial of Remibrutinib for Hidradenitis Suppurativa
Phase 3
555
about 3.7 years
12–100
36 sites in AR, AZ, CA +18
About this study
This trial is testing whether remibrutinib, a medication, is effective and safe in treating moderate to severe hidradenitis suppurativa. Participants will receive either placebo or different doses of remibrutinib over 1358 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo 1
- 2.Take Placebo 2
- 3.Take Remibrutinib Dose A
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral (Oral Tablet)
Secondary: Incidence of treatment emergent adverse events and serious adverse events during the study, Percentage change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 16, Proportion of participants with clinical response in HS related skin pain (NRS 30), at worst at Week 16